Innate immunity and antibiotic activity in resistant bacterial infections in immunocompromised hosts

Antimicrobial resistance (AMR) is particularly difficult to manage in immunocompromised hosts, in whom impaired bacterial containment and clearance can coexist with restricted treatment options, altered drug exposure, and anatomically complex infection sites. Susceptibility testing and pharmacokinetic/pharmacodynamic (PK/PD) assessment guide antibiotic treatment, while host defenses help determine whether injured bacteria are cleared. This Review examines the host–antibiotic interface in resistant bacterial infection, with emphasis on how innate immunity contributes to antibacterial activity in immunocompromised populations. We distinguish quantitative and qualitative defects in neutrophils, monocyte hyporesponsiveness, complement impairment, barrier disruption, and combined host deficits, and consider how bacterial burden, infection compartment, and protected intracellular or extracellular populations modify drug–host interactions. Experimental studies show that immune function influences bacterial growth, clearance, and observed antibiotic exposure–response relationships. Antibiotic-induced changes in bacterial morphology, microbial-product release, and immune recognition may promote clearance or inflammatory injury depending on pathogen, burden, timing, and host state. Adjunctive approaches, including colony-stimulating factors, interferon-γ, innate agonists, pathogen-specific antibodies, antibody–antibiotic conjugates, and phage–antibiotic combinations, vary substantially in mechanism and strength of supporting evidence. Clinical assessment of adjunctive strategies requires evidence of improved infection outcomes as well as biological activity. We propose a research-oriented framework integrating antibacterial exposure, bacterial phenotype and burden, infection compartment, and host immune function to guide mechanistic investigation, while retaining effective antibiotic treatment and source control when indicated as the foundations of clinical care.

Authors

Institutions

Publication Details

Journal
Frontiers in Cellular and Infection Microbiology
Published
2026-10-29
DOI
https://doi.org/10.3389/fcimb.2026.2002377
Primary Topic
Neutropenia and Cancer Infections
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Innate immunity and antibiotic activity in resistant bacterial infections in immunocompromised hosts

Haizhen Cui, Yiming Guo, Yueyao Jiang, Yao Sun et al.
Frontiers in Cellular and Infection Microbiology
Neutropenia and Cancer Infections
article

Innate immunity and antibiotic activity in resistant bacterial infections in immunocompromised hosts

Haizhen Cui, Yiming Guo, Yueyao Jiang, Yao Sun, Qian Yu
article en

Abstract

Antimicrobial resistance (AMR) is particularly difficult to manage in immunocompromised hosts, in whom impaired bacterial containment and clearance can coexist with restricted treatment options, altered drug exposure, and anatomically complex infection sites. Susceptibility testing and pharmacokinetic/pharmacodynamic (PK/PD) assessment guide antibiotic treatment, while host defenses help determine whether injured bacteria are cleared. This Review examines the host–antibiotic interface in resistant bacterial infection, with emphasis on how innate immunity contributes to antibacterial activity in immunocompromised populations. We distinguish quantitative and qualitative defects in neutrophils, monocyte hyporesponsiveness, complement impairment, barrier disruption, and combined host deficits, and consider how bacterial burden, infection compartment, and protected intracellular or extracellular populations modify drug–host interactions. Experimental studies show that immune function influences bacterial growth, clearance, and observed antibiotic exposure–response relationships. Antibiotic-induced changes in bacterial morphology, microbial-product release, and immune recognition may promote clearance or inflammatory injury depending on pathogen, burden, timing, and host state. Adjunctive approaches, including colony-stimulating factors, interferon-γ, innate agonists, pathogen-specific antibodies, antibody–antibiotic conjugates, and phage–antibiotic combinations, vary substantially in mechanism and strength of supporting evidence. Clinical assessment of adjunctive strategies requires evidence of improved infection outcomes as well as biological activity. We propose a research-oriented framework integrating antibacterial exposure, bacterial phenotype and burden, infection compartment, and host immune function to guide mechanistic investigation, while retaining effective antibiotic treatment and source control when indicated as the foundations of clinical care.

Frontiers in Cellular and Infection MicrobiologyVol. 16
Jilin University (CN)
Natural Science Foundation of Jilin Province, Jilin University, Department of Science and Technology of Jilin Province
Good health and well-being
Openalex Percentile: Top 16%
Neutropenia and Cancer Infections
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon